Literature DB >> 28409436

9p24 abnormalities in hematologic malignancies with a focus on diffuse large B-cell lymphoma.

Dilan A Patel1, Andrew W Hahn2, Mike G Martin3.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28409436     DOI： 10.1007/s12032-017-0957-7

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  3 in total

1.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

2.  Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies.

Authors:  Katrien Van Roosbroeck; Julio Finalet Ferreiro; Thomas Tousseyn; Jo-Anne van der Krogt; Lucienne Michaux; Barbara Pienkowska-Grela; Ivan Theate; Pascale De Paepe; Daan Dierickx; Chantal Doyen; Natalie Put; Jan Cools; Peter Vandenberghe; Iwona Wlodarska
Journal:  Genes Chromosomes Cancer       Date:  2016-02-06       Impact factor: 5.006

3.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.